Biotechnology Supply Chain Security Law In Russia.

1. Introduction

Biotechnology Supply Chain Security Law in Russia refers to the legal and regulatory framework governing the secure production, procurement, transportation, storage, import, export and distribution of biotechnology-related products and materials.

The framework seeks to protect biotechnology supply chains against:

Counterfeit and substandard medicines.

Illegal trafficking of biological materials.

Theft or diversion of dangerous microorganisms.

Unauthorized export of human biological samples.

Contamination during manufacturing and transportation.

Cybersecurity threats affecting biotechnology infrastructure.

Disruption of essential pharmaceutical supplies.

Unauthorized transfer of genetic and biological information.

Illegal trade in genetically modified organisms (GMOs).

Dependence on insecure international suppliers.

Russia does not have one comprehensive statute entitled the Biotechnology Supply Chain Security Act. Instead, supply-chain security is governed by several interconnected federal laws, government regulations, customs rules, export-control requirements and Eurasian Economic Union (EAEU) standards.

The central legal objective is to ensure that biotechnology products remain safe, traceable, properly authorized and protected throughout their commercial and scientific lifecycle.

2. Principal legislative framework

The most important legislation includes:

LegislationRegulatory significance
Federal Law No. 492-FZ of 2020Biological safety and prevention of biological threats
Federal Law No. 61-FZ of 2010Circulation, manufacturing, storage and transportation of medicines
Federal Law No. 183-FZ of 1999Export control over dual-use goods and technologies
Federal Law No. 86-FZ of 1996Genetic engineering activities
Federal Law No. 29-FZ of 2000Food quality and safety
Federal Law No. 323-FZ of 2011Public health protection
Federal Law No. 152-FZ of 2006Personal data protection
Federal Law No. 289-FZ of 2018Customs regulation

These laws operate together to establish controls over the movement of biological products, pharmaceutical ingredients, laboratory materials and sensitive biotechnology technologies.

3. Biological Security under Federal Law No. 492-FZ of 2020

Federal Law No. 492-FZ, On Biological Safety in the Russian Federation, 30 December 2020

This is one of the central statutes governing biotechnology supply-chain security in Russia.

Its principal purpose is to protect the population and environment against dangerous biological factors and prevent biological threats.

Important provisions

Section 1 – Biological safety and biological risks

The law defines biological safety and biological risks. It provides the conceptual foundation for regulating activities involving dangerous biological agents.

Section 4 – Activities ensuring biological safety

The legislation establishes the framework for government and organizational activities designed to prevent biological threats.

Section 5 – Government powers

Federal and regional authorities receive responsibilities relating to biological safety, monitoring and the coordination of relevant measures.

Section 7 – Responsibilities of organizations

Organizations engaged in relevant activities must comply with applicable biological safety requirements. This is particularly important for laboratories, biotechnology manufacturers and organizations handling dangerous biological materials.

Section 8 – Biological threats

The law recognizes biological threats arising from dangerous biological factors and potentially hazardous biological facilities.

Section 11 – Biological collections

This provision concerns collection activities involving pathogenic microorganisms and viruses. It is particularly relevant to the management of biological collections, research institutions and pathogen repositories.

Section 12 – Prevention of accidents and sabotage

This provision addresses prevention of accidents and sabotage at potentially dangerous biological facilities, as well as other deliberate biological threats.

Section 13 – Biological risk monitoring

It establishes the legal basis for monitoring biological risks.

Section 14 – State information system

It provides for a state information system in the field of biological safety.

Section 16 – Liability

The legislation provides for responsibility for violations of biological safety requirements.

Consultant Plus+2

Importance for supply-chain security

Consider a Russian biotechnology company transporting pathogenic microorganisms to a research institution.

The company must consider:

Whether the material is legally permitted to be handled and transported.

Whether the receiving institution is authorized to undertake the relevant activity.

Whether applicable containment and safety requirements are satisfied.

Whether transportation arrangements protect against accidental release.

Whether the material is protected against unauthorized access or diversion.

The law therefore connects biological safety with the security of the organizations and infrastructure through which biological materials move.

4. Pharmaceutical Supply Chain Security under Federal Law No. 61-FZ of 2010

Federal Law No. 61-FZ, On Circulation of Medicines, 12 April 2010

This legislation is particularly important for pharmaceutical biotechnology, vaccines, biological medicines, therapeutic proteins, monoclonal antibodies and other medicinal products.

Article 1 establishes that the legislation covers the development, research, registration, production, quality control, storage, transportation, import, export, distribution and destruction of medicines.

Article 4 also recognizes pharmaceutical substances and medicines produced using biotechnology.

CIS Legislation+1

Main legal requirements

A. Manufacturing security

Manufacturers must comply with applicable manufacturing and quality requirements. Manufacturing controls help prevent contamination, unauthorized production and the introduction of substandard products.

B. Storage security

Biological medicines frequently require controlled temperature conditions.

For example, certain vaccines and biological preparations require refrigerated or frozen storage.

Failure to maintain the required conditions can compromise product quality and effectiveness.

C. Transportation security

Transportation arrangements must preserve the quality and safety of medicines throughout distribution.

Relevant controls include:

Temperature monitoring.

Appropriate packaging.

Shipment documentation.

Protection against tampering.

Verification of authorized distributors.

Procedures for investigating transportation failures.

D. Import and export controls

Imported pharmaceutical products and biological substances must comply with applicable Russian registration, customs and authorization requirements.

E. Counterfeit medicine prevention

The legislation provides a framework for preventing the circulation of falsified, counterfeit and substandard medicines.

Strategic medicines and supply security

An important development occurred through Federal Law No. 268-FZ of 23 July 2025.

It introduced the concept of strategically significant medicines into Article 4 of Federal Law No. 61-FZ.

These are medicines considered necessary to meet priority healthcare requirements, with production required to be provided within Russian territory.

The amendment became effective on 1 September 2025.

This development strengthens the connection between pharmaceutical regulation, domestic manufacturing capacity and national supply resilience.

CIS Legislation+1

5. Export Control and Dual-Use Biotechnology Materials

Federal Law No. 183-FZ of 1999, On Export Control

Russia regulates certain biotechnology products because biological materials, microorganisms, toxins, equipment and technologies may have both civilian and military applications.

This is known as the dual-use problem.

For example, biological materials may be used for:

Medical diagnostics.

Vaccine research.

Pharmaceutical development.

Scientific experimentation.

Research involving potentially dangerous biological agents.

However, certain controlled materials and technologies may also create security risks if diverted to prohibited purposes.

Important regulatory instruments

Federal Law No. 183-FZ of 1999.

Government Resolution No. 1287 of 16 July 2022, concerning the list of controlled microorganisms, toxins, equipment and technologies.

Government Resolution No. 517 of 15 August 2005, concerning permission from the Export Control Commission in specified transactions.

Government Resolution No. 634 of 29 August 2001, regulating foreign economic activities involving controlled microorganisms, toxins, equipment and technologies.

Under the applicable export-control framework, certain foreign economic transactions require authorization from the competent authorities.

The Russian Federation also identified these instruments in its 2023 submission to the United Nations Biological Weapons Convention Working Group.

UN Official Document System+1

Legal significance

A biotechnology company cannot automatically assume that biological samples are exempt from export controls simply because they are being sent abroad for scientific research.

The classification of the material, its intended use, the identity of the recipient and the applicable export-control rules must be examined.

This is particularly important for:

Human tissue samples.

Blood and plasma specimens.

Pathogenic microorganisms.

Genomic research materials.

Controlled laboratory technologies.

6. Pharmaceutical Serialization and Supply Chain Traceability

Russia has introduced a pharmaceutical tracking system to strengthen the identification and monitoring of medicines.

The national product-marking system, commonly associated with Chestny ZNAK, supports the identification and tracking of regulated products.

For medicines, serialization helps identify individual packages and monitor their movement through the legal distribution system.

Exporting to Russia: Everything You Need to Know About Chestny Znak - Benefits and Procedure

 

 

Проверить подлинность лекарств ямальцам поможет мобильный «Честный Знак» | «Красный Север»

 

 

Сериализация фармацевтики. Оборудование для производителей.

 

10

 

Main functions

1. Product identification

Individual medicine packages receive identification codes in accordance with the applicable marking rules.

2. Distribution monitoring

Supply-chain participants transmit relevant information about product movement through the prescribed information system.

3. Counterfeit detection

Verification of identification codes helps identify suspicious products and unauthorized circulation.

4. Recall management

Traceability information can assist authorities and manufacturers in identifying affected products when a safety or quality problem occurs.

5. Accountability

The system improves the ability to establish which participants handled a particular pharmaceutical product.

The Russian pharmaceutical track-and-trace regime became mandatory in stages, with broad mandatory operation beginning on 1 July 2020.

CMS Law+1

An important distinction is that medicine serialization does not automatically cover every biotechnology material. Human tissue samples, research microorganisms and laboratory reagents may be governed by different regulatory and identification requirements.

7. Customs and International Biotechnology Supply Chains

The EAEU Customs Code and Russian Federal Law No. 289-FZ of 2018 govern important aspects of the movement of biotechnology products across borders.

The applicable controls depend on the nature and classification of the goods.

For example:

Biotechnology materialPotential regulatory concern
Human tissue samplesExport permissions and export control
Blood and plasmaBiological-material restrictions
VaccinesMedicine registration and transport requirements
Genetically modified materialsGMO and biosafety requirements
Pathogenic microorganismsBiological safety and export control
Pharmaceutical ingredientsCustoms classification and pharmaceutical regulation
Laboratory equipmentTechnical and possible dual-use controls

A company exporting biological samples should not rely exclusively on a commercial invoice or a general healthcare authorization.

It must examine whether additional export-control or customs permissions are required.

8. Important Russian Case Laws and Judicial Decisions

Russian courts have considered disputes involving the export of human biological samples, customs restrictions and dual-use export controls. These decisions are particularly useful for understanding biotechnology supply-chain security.

Case 1: LLC National BioService v. North-West Electronic Customs

Important judicial decision

Case No.: A56-73690/2023

Court: Arbitration Court of Saint Petersburg and Leningrad Region

Decision date: 24 October 2023

Legal provision: Article 16.3, Russian Code of Administrative Offences.

Facts

National BioService exported human blood and plasma samples from Russia to Switzerland.

The shipment contained 535 biological samples obtained from patients with colorectal cancer and healthy control subjects.

The company declared that the materials were intended for scientific and laboratory research.

It also submitted a permission document from Roszdravnadzor.

However, customs authorities determined that the biological materials fell within a category of goods subject to export-control restrictions.

Legal issue

Whether a healthcare authorization was sufficient to establish compliance with the separate export-control requirements.

Judgment

The court rejected the company's challenge and upheld the administrative penalty of RUB 50,000.

It considered the applicable export-control restrictions and the classification of the biological materials.

Legal principle

A healthcare authorization does not automatically replace a separate export-control authorization where the latter is legally required.

Importance

This case demonstrates that biotechnology exporters must independently examine healthcare regulation, customs requirements and national export-control restrictions.

sudact.ru+1

Case 2: LLC StarExpert v. North-West Electronic Customs

Case No.: A56-36283/2023

Court: Arbitration Court of the North-Western District

Decision date: 20 February 2024

Reference: F07-690/24

Legal provision: Article 16.3, Russian Code of Administrative Offences.

Facts

StarExpert exported frozen human biological materials to a laboratory in the United States.

The shipment consisted of histological samples obtained from 148 patients suffering from adenocarcinoma.

The exporter argued that the samples were intended for diagnostic research and were not pharmaceutical substances or medicines.

Customs authorities subsequently examined the transaction and concluded that the biological samples were subject to export-control restrictions.

Legal issue

Whether the exporter could rely on the declared diagnostic purpose to avoid additional export-control requirements.

Judgment

The court upheld the lower court's decision rejecting the company's challenge.

The court considered that the documents, including the Roszdravnadzor authorization, did not sufficiently establish that the samples were intended exclusively for the relevant therapeutic or diagnostic purposes.

The fact that the goods had initially been released by customs did not eliminate the possibility of subsequent administrative enforcement.

Legal principle

The declared civilian purpose of biological materials must be supported by adequate documentation.

Importance

This decision is particularly relevant to biotechnology businesses involved in international clinical research, diagnostic testing, genomic research and human tissue transportation.

sudact.ru+1

Case 3: StarExpert – Human Biological Materials Export Dispute

Case No.: A56-36286/2023

Court: Russian arbitration judicial system

Decision date: 12 March 2024

Facts

The dispute involved the export of human biological samples under international commercial arrangements.

The exporter relied on a Roszdravnadzor authorization indicating that the samples were intended for diagnostic investigations.

However, the contractual arrangements allowed foreign customers to use the biological materials for their own purposes and potentially transfer them to third parties.

The authorities questioned whether the declared medical and diagnostic purpose was adequately established.

Legal issue

Whether a general research or diagnostic authorization was sufficient when the contractual arrangements did not adequately restrict the use and onward transfer of biological materials.

Judicial significance

The court materials demonstrate the importance of examining:

The actual purpose of export.

The identity of the foreign recipient.

Contractual restrictions on onward transfer.

The documentation establishing the intended use.

The need for additional export-control authorization.

Legal principle

The legal assessment of a biological-material shipment must consider not only the nature of the product but also its intended end use and the surrounding contractual arrangements.

sudact.ru

Case 4: StarExpert – Appeal Decision

Case No.: A56-36283/2023

Court: Thirteenth Arbitration Court of Appeal

Decision date: 26 October 2023

Decision reference: 13AP-28680/23

The company challenged the first-instance decision concerning its export of human tissue samples.

It argued that the materials were intended for diagnostic purposes and that the applicable exception to export controls should apply.

The appellate court rejected the challenge.

The court emphasized that the documents submitted by the exporter did not adequately establish the relevant medical and diagnostic purpose.

Legal significance: The case reinforces the distinction between general authorization for the movement of biological samples and compliance with specific national export-control requirements.

sudact.ru+1

Comparative summary of the cases

CasePrincipal legal issueImportance
A56-73690/2023Export of blood and plasma samplesSeparate export-control compliance
A56-36283/2023Export of human tissue to the USAProof of actual intended use
A56-36286/2023International transfer arrangementsEnd-user and onward-transfer controls
13AP-28680/23Appeal concerning human tissue exportEvidence required for regulatory exceptions

Academic observation: These are mainly administrative and customs disputes rather than Supreme Court judgments establishing a general doctrine of biotechnology supply-chain security. Nevertheless, they provide concrete judicial guidance on the practical application of export-control legislation.

9. Administrative and Criminal Liability

Biotechnology supply-chain violations can produce administrative, civil or criminal consequences depending on the conduct and applicable statutory provisions.

A. Administrative liability

Article 16.3 of the Russian Code of Administrative Offences concerns non-compliance with prohibitions and restrictions applicable to the import or export of goods.

Other administrative provisions may apply to violations of pharmaceutical, sanitary, customs and licensing requirements.

B. Criminal liability

The Russian Criminal Code contains provisions relevant to dangerous biological materials and illegal exports.

Important examples include:

Article 189: Illegal export or transfer of controlled goods, technologies and services in circumstances covered by the provision.

Article 248: Violation of safety rules when handling microbiological or other biological agents or toxins, where the statutory consequences occur.

Article 355: Activities involving weapons of mass destruction.

Article 189 is particularly relevant where controlled dual-use biotechnology goods are illegally exported or transferred with the requisite criminal elements.

The 2023 Russian submission to the Biological Weapons Convention also identifies criminal liability under the export-control framework.

UN Official Document System+1

 

C. Civil liability

A biotechnology supplier may face contractual or civil liability where:

Contaminated materials cause financial losses.

Defective biological products injure consumers.

A supplier breaches contractual quality obligations.

Improper transportation damages temperature-sensitive medicines.

A manufacturer fails to meet agreed specifications.

Civil liability must be assessed under the Russian Civil Code and applicable product-specific legislation.

10. Role of Russian Regulatory Authorities

Several government institutions participate in biotechnology supply-chain regulation.

AuthorityPrincipal responsibility
Ministry of HealthPharmaceutical policy and regulation
RoszdravnadzorPharmaceutical and healthcare supervision
RospotrebnadzorSanitary and epidemiological supervision
Federal Customs ServiceCustoms compliance and border controls
FSTECTechnical and export-control functions
Ministry of Industry and TradeIndustrial and pharmaceutical policy
RosselkhoznadzorVeterinary and phytosanitary supervision

Their responsibilities overlap in certain transactions.

For example, exporting human biological samples may involve healthcare documentation, customs declarations and export-control authorization.

11. Major Legal Challenges

Despite the existing legislative framework, several important challenges remain.

1. International supply-chain fragmentation

Biotechnology products often pass through several countries, distributors and laboratories. Different regulatory systems can create authorization conflicts.

2. Counterfeit biological medicines

Counterfeit vaccines and biological medicines can create serious public-health risks. Product identification and distribution monitoring are therefore important.

3. Cold-chain failures

Temperature-sensitive medicines may lose their quality when refrigeration or transportation conditions fail.

4. Biological sample diversion

Human tissues, blood samples and other biological materials may be transferred to foreign recipients. Controlling their actual end use is a significant regulatory challenge.

5. Cybersecurity vulnerabilities

Digital pharmaceutical tracking systems and biotechnology manufacturing networks may be exposed to unauthorized access, manipulation and operational disruption.

6. Dependence on foreign suppliers

Restrictions on international trade, transport disruption and shortages of imported pharmaceutical ingredients can affect domestic manufacturing.

7. Regulatory coordination

Different authorities may have responsibilities over the same shipment. Businesses must identify all applicable permissions rather than assuming that one approval satisfies every regulatory requirement.

12. Compliance Framework for Biotechnology Companies in Russia

A biotechnology company operating in Russia should establish an integrated compliance programme.

Recommended supply-chain compliance lifecycle

Supplier verification

Verify supplier identity, authorization, qualifications and product provenance.

Product classification

Determine whether the material is a medicine, biological sample, microorganism, GMO or controlled dual-use product.

Regulatory authorization

Obtain applicable pharmaceutical, sanitary, customs and export-control permissions.

Secure manufacturing

Apply relevant quality management, contamination prevention and manufacturing controls.

Transportation monitoring

Maintain appropriate packaging, temperature records, shipment documentation and security procedures.

Traceability

Maintain records of product identification, custody, distribution and receipt.

Incident management

Establish procedures for recalls, contamination, theft, diversion and unauthorized access.

13. International Legal Framework

Russian biotechnology supply-chain security also interacts with international legal instruments.

Important examples include:

Biological Weapons Convention (1972): Prohibits the development, production and stockpiling of biological and toxin weapons.

Convention on Biological Diversity (1992): Establishes international obligations concerning biodiversity conservation and sustainable use.

Cartagena Protocol on Biosafety (2000): Provides an international framework for the safe transfer, handling and use of living modified organisms. Russia is not a party to this Protocol, so its provisions should not be treated as directly binding Russian treaty obligations.

EAEU regulatory framework: Establishes common rules relevant to pharmaceutical circulation and technical regulation within the Eurasian Economic Union.

The Biological Weapons Convention is particularly relevant to preventing the diversion of biological materials and technologies for prohibited purposes.

UN Official Document System+1

14. Critical Legal Analysis

The Russian biotechnology supply-chain security framework has three interconnected dimensions.

First: Public-health protection.

Federal Law No. 61-FZ establishes controls over the pharmaceutical lifecycle, including manufacturing, transportation, storage and distribution.

Second: National biological security.

Federal Law No. 492-FZ addresses biological risks, dangerous biological facilities, pathogen collections and monitoring systems.

Third: National security and international trade.

Federal Law No. 183-FZ and associated regulations control certain international transfers of biological materials and dual-use technologies.

An important legal distinction is that these three dimensions are not interchangeable. Compliance with pharmaceutical legislation does not automatically establish compliance with biological safety or export-control legislation.

The National BioService and StarExpert cases illustrate this problem: companies may possess healthcare-related documentation but still face administrative enforcement because separate export-control requirements have not been satisfied.

A further challenge is ensuring that supply-chain security does not unnecessarily obstruct legitimate scientific research, international medical cooperation and the movement of biological materials for lawful diagnostic purposes.

The legal system therefore has to balance national security, public health, commercial activity and scientific freedom.

15. Conclusion

Biotechnology Supply Chain Security Law in Russia is a developing and interconnected area of regulatory law.

Its principal foundations are Federal Law No. 492-FZ on Biological Safety, Federal Law No. 61-FZ on Circulation of Medicines and Federal Law No. 183-FZ on Export Control.

Together, these laws establish a framework for protecting biological materials, pharmaceutical products, biotechnology infrastructure and international supply-chain transactions.

The judicial decisions in Cases A56-73690/2023, A56-36283/2023 and A56-36286/2023 demonstrate that exporters must pay particular attention to biological-material classification, intended use, end-user verification and separate export-control permissions.

Ultimately, the effectiveness of biotechnology supply-chain security depends on combining regulatory authorization, product traceability, biological safety, secure transportation, supplier accountability and effective judicial enforcement.

16. Important legislation and research references

Legal sourceSubject
Federal Law 492-FZ (2020)Biological safety
Federal Law 61-FZ (2010)Medicines and pharmaceutical supply chains
Federal Law 183-FZ (1999)Export control
Federal Law 268-FZ (2025)Strategically significant medicines
Government Resolution 1287 (2022)Controlled biological materials and technologies
Government Resolution 517 (2005)Export Control Commission permissions
Russian Code of Administrative OffencesAdministrative enforcement
Russian Criminal CodeCriminal enforcement

Primary research materials:

Federal Law No. 492-FZ – Biological Safety.

Federal Law No. 61-FZ – Circulation of Medicines.

Federal Law No. 268-FZ – Strategically Significant Medicines.

Russian Federation submission to the Biological Weapons Convention Working Group, 2023.

National BioService – Case A56-73690/2023.

StarExpert – Case A56-36283/2023.

StarExpert – Case A56-36286/2023.

Research note: This is an academic overview, not a substitute for checking the current consolidated Russian legislation, applicable EAEU regulations and the precise classification of a particular biological shipment.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT